Rallybio
Manufacturing · Connecticut, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
234 Church St Ste 1020, New Haven, Conne...Phone Number
(203) 859-3820Website
www.rallybio.comRevenue
<$5 MillionStock Symbol
RLYBIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About Rallybio
Rallybio is a clinical-stage biotechnology company focused on identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. Since its launch in January 2018, Rallybio has built a portfolio of promising product candidates, which are now in development to address rare diseases in the areas of hematology, immuno-inflammation, and metabolism.Explore more
Rallybio Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Rallybio your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when Rallybio launches new products
Funding: Get notified immidiatlly once Rallybio has new funding data
Congratulate Masked Content for being promoted to Masked Content at Rallybio
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Rallybio, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if Rallybio had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on Rallybio recently announced quarterly report
Check if Rallybio has recently received funding, and reach out quickly before it becomes old news!
Check out if Rallybio is spiking on competitors!
Recommended Actions
Find VP level buyers at Rallybio
Find 2 more new buyers
Compare Similar Companies to Rallybio
Compare insights from companies similar to Rallybio, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Rallybio is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Rallybio is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Rallybio.
Rallybio financials insights
Gather financial insights about Rallybio, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2018
Series A
$37M
2020
Share Placement
$93.2M
Series B
$145M
2021
Share Placement
$80.6M
Rallybio Tech Stack
A closer look at the technologies used by Rallybio
Most Recent Scoops
Project
Rallybio is currently advancing two highly selective cyclin-dependent kinase inhibitors AVZO021, a selective CDK2 inhibitor, and AVZO023, a selective CDK4 inhibitor in ongoing Phase I studies in the United States, with partners making parallel progress within Greater China.
Pharmaceuticals
Project
Rallybio is currently advancing two bispecific antibody-drug conjugates AVZO1418, targeting EGFR and HER3, and AVZO103, targeting NECTin4 and TROP2 in ongoing Phase I studies in the United States, with partners making parallel progress within Greater China.
Medical Research, Pharmaceuticals
Project
Rallybio is currently in the early stages of the Phase I portion of the Beacon-1 study evaluating AVZO103, a bispecific antibody-drug conjugate targeting NECTin4 and TROP2, with clinical data from the program expected to be shared later this year.
Medical Research, Pharmaceuticals, Clinical Operations
Project
Rallybio has dosed over 30 patients in the Phase I portion of the Aventine-1 study evaluating AVZO1418, a bispecific antibody-drug conjugate targeting EGFR and HER3, since initiating the study in mid-2025, with encouraging initial clinical activity observed across multiple tumor types and a potentially differentiated tolerability profile, particularly regarding hematologic adverse events.
Medical Research, Pharmaceuticals, Clinical Operations
Project
Medical Research, Clinical Operations
Rallybio News & Media
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Taylor Morrison Home Corporation (NYSE - TMHC), Rallybio Corporation (Nasdaq – RLYB), InMed Pharmaceuticals, Inc. (Nasdaq – INM), KalVista Pharmaceuticals, Inc. (Nasdaq – KALV)
BALA CYNWYD, Pa., June 02, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.Rallybio Corporation (RLYB) M&A Call Prepared Remarks Transcript
Rallybio Corporation (RLYB) M&A Call June 1, 2026 8:30 AM EDTCompany ParticipantsSteve Uden - Co-Founder, President, CEO & DirectorAthena...RallyBio tries again for reverse merger, this time with Avenzo
It's the second attempt for the rare disease company, which initially announced plans to merge with Candid Therapeutics before the immune drug developer was bought by UCB.Rallybio merger scrapped; New Haven biotech to receive $50M breakup fee
New Haven-based Rallybio Corp. said Monday its planned merger with a San Diego biotechnology company has been terminated.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Rallybio
Sign Up For FreeTo access detailed company insights
Rallybio is a clinical-stage biotechnology company focused on identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. Since its launch in January 2018, Rallybio has built a portfolio of promising product candidates, which are now in development to address rare diseases in the areas of... Read More
